Issue 12, 2019

A small molecule drug conjugate (SMDC) of DUPA and a duocarmycin built on the solid phase

Abstract

In a proof-of-concept study, solid phase synthesis allowed the rapid generation of a small molecule drug conjugate in which the glutamate carboxypeptidase II (GCPII) targeting small molecule DUPA was conjugated to the alkylating subunit of the potent cytotoxin duocarmycin SA. The targeted SMDC contained a cathepsin B cleavable linker, which was shown to be active and selective against cathepsin B over-expressing and GCPII-expressing tumour cell lines.

Graphical abstract: A small molecule drug conjugate (SMDC) of DUPA and a duocarmycin built on the solid phase

Supplementary files

Article information

Article type
Research Article
Submitted
15 May 2019
Accepted
12 Nov 2019
First published
27 Nov 2019

Med. Chem. Commun., 2019,10, 2170-2174

A small molecule drug conjugate (SMDC) of DUPA and a duocarmycin built on the solid phase

A. M. Beekman, M. M. D. Cominetti, O. C. Cartwright, D. L. Boger and M. Searcey, Med. Chem. Commun., 2019, 10, 2170 DOI: 10.1039/C9MD00279K

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Spotlight

Advertisements